BIOMAT Database Logo BIOMAT Database Logo

Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated. 1998

N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
Department of Medicine II, Tokyo Women's Medical University, Japan. naomi-hi@hi-ho.ne.jp

Non-islet cell tumor hypoglycemia (NICTH) is one of major causes of fasting hypoglycemia. In some patients with NICTH, insulin-like growth factor II (IGF-II) produced by and secreted from the tumors is thought to be a hypoglycemic agent. In patients with NICTH, the major form of IGF-II is high molecular weight form of IGF-II, designated as big IGF-II. The generation of big IGF-II in the NICTH syndrome is unclear. It has been reported that in the patients with NICTH big IGF-II lacks normal E-domain O-linked glycosylation, suggesting that the patient's big IGF-II might be generated by abnormal processing of pro-IGF-II. However, we have found that the apparent size of big IGF-II varies in sera from the patients with NICTH, and that there is a possibility that slower migration pattern of IGF-II might be because of a different size of sugar moiety attached to pro-IGF-II. In the present study using the sera from 10 patients with NICTH, we investigated the effect of O-glycosidase digestion on migration of IGF-II and analyzed the results by Western immunoblot. By Western immunoblot analysis the big IGF-II was reduced in size to 9.5 kDa in the enzyme-treated sera of the 10 patients with NICTH. The migration pattern is similar to that observed in sera of normal subjects after O-glycosidase digestion. These data indicate that big IGF-II from patients with NICTH is O-glycosylated, and the sizes of the sugar moiety are larger than those from normal subjects suggesting abnormal glycosylation in NICTH.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D005260 Female Females
D006026 Glycoside Hydrolases Any member of the class of enzymes that catalyze the cleavage of the glycosidic linkage of glycosides and the addition of water to the resulting molecules. Endoglycosidase,Exoglycosidase,Glycohydrolase,Glycosidase,Glycosidases,Glycoside Hydrolase,Endoglycosidases,Exoglycosidases,Glycohydrolases,Hydrolase, Glycoside,Hydrolases, Glycoside

Related Publications

N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II.
May 1990, The Journal of clinical investigation,
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
High molecular weight form insulin-like growth factor II-producing mesenteric sarcoma causing hypoglycemia.
October 2004, Internal medicine (Tokyo, Japan),
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
July 2005, The Journal of clinical endocrinology and metabolism,
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
Retroperitoneal solitary fibrous tumor-induced hypoglycemia associated with high molecular weight insulin-like growth factor II.
December 2010, Clinical medicine & research,
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
Insulin-like growth factors and non-islet cell tumor hypoglycemia.
September 1993, Metabolism: clinical and experimental,
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
A case of gastric cancer with non-islet cell tumor hypoglycemia detected by insulin-like growth factor II.
August 2010, Pathology international,
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
Gastric neuroendocrine carcinoma with non-islet cell tumor hypoglycemia associated with enhanced production of insulin-like growth factor II.
January 2013, Internal medicine (Tokyo, Japan),
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.
December 1981, The New England journal of medicine,
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.
May 1982, The New England journal of medicine,
N Hizuka, and I Fukuda, and K Takano, and K Asakawa-Yasumoto, and Y Okubo, and H Demura
[Solitary fibrous tumor of the pleura with elevated high-molecular-weight insulin-like growth factor II and hypoglycemia].
October 1999, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
Copied contents to your clipboard!